VK

Venkateswaran Kailasam Kalpathy

Active Director Designated Partner DIN 05272338
DIN 05272338 First appointment May 2012 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2012
Shareholding value β€’β€’β€’β€’ Premium profile

About Venkateswaran Kailasam Kalpathy

Data last updated:

Venkateswaran Kailasam Kalpathy is a Designated Partner at Stelios Pharmaceuticals Llp (since 2012). The company operates in Pharma.

DIN 05272338
Primary Designation Designated Partner
Industry Pharma
First Appointment 10 May 2012
Oldest Company Age 14 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner10 May 20122012Active

Board colleagues of Venkateswaran Kailasam Kalpathy

NameDINCompanyDesignation
Vasanthi Venkateswaran05213270Stelios Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Stelios Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Venkateswaran Kailasam Kalpathy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Venkateswaran Kailasam Kalpathy

Venkateswaran Kailasam Kalpathy currently holds 1 directorship: Stelios Pharmaceuticals Llp (Designated Partner, since 10 May 2012).

Venkateswaran Kailasam Kalpathy was first appointed on 10 May 2012 as Designated Partner at Stelios Pharmaceuticals Llp.

The current boards of Venkateswaran Kailasam Kalpathy's companies include Vasanthi Venkateswaran (Stelios Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available